Clinical Trials Logo

Clinical Trial Summary

This study compares the diagnostic performance of Endoscopic ultrasound (EUS) guided fine needle aspiration and EUS guided core biopsy (SharkCore) in patients with a solid pancreatic mass.

Clinical Trial Description

Endoscopic ultrasound (EUS) guided fine needle aspiration (FNA) and fine needle biopsy (FNB) are the standard methods for obtaining tissue samples from tumours of the pancreas. The diagnostic accuracy by strict criteria is around 75-80%. A non diagnostic sample causes delay and the need for a repeat procedure. To date no significant difference has been found between standard FNA and standard FNB needles. A novel opposing bevel design (SharkCore) needle for FNB may provide better diagnostic performance. The aim of this study is to compare the performance of a standard needle and the Sharkcore needle. Patients attending for routine biopsy of a suspected pancreatic tumour will be invited to participate. All participants will have 3 samples taken with each needle. The samples from each needle will be processed and reported separately with the pathologists blinded as to the report from the other needle. Following the procedure participants will be observed as normal in the recovery area and allowed home later. Further study participation is limited to 1 telephone call at 7 days. Participants will be asked if they have developed any new symptoms since the procedure and whether they have had to seek medical attention for this.The risks of the study procedure are the same as those of a non study procedure. Both needle types are in routine use in our unit. The study will be performed in the endoscopy unit of the Freeman hospital. The study is funded by a grant from Medtronic the company who make the Sharkcore needle. The study is planned to recruit 108 participants over 10 months with a further 6 months of follow up. If the new needle is found to perform better its routine use will potentially reduce the delay experienced by patients as well as the cost incurred by repeat procedures. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03532347
Study type Interventional
Source Newcastle-upon-Tyne Hospitals NHS Trust
Status Active, not recruiting
Phase N/A
Start date May 22, 2017
Completion date November 4, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01313416 - Gemcitabine and CT-011 for Resected Pancreatic Cancer Phase 2
Recruiting NCT01411072 - Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer N/A
Active, not recruiting NCT01448668 - Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV) N/A
Completed NCT01155882 - Registry Study - Whipple at the Splenic Artery
Active, not recruiting NCT03682744 - CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) Phase 1
Terminated NCT01888965 - Maintenance Dovitinib for Colorectal and Pancreas Cancer Phase 2
Active, not recruiting NCT01771146 - Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer N/A
Terminated NCT00864513 - Study of Pemetrexed for Second-Line Pancreas Cancer Phase 2
Recruiting NCT03264404 - Azacitidine and Pembrolizumab in Pancreatic Cancer Phase 2
Recruiting NCT03621982 - Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Phase 1
Recruiting NCT02905578 - A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) Phase 2
Recruiting NCT03199586 - Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Phase 1
Not yet recruiting NCT03760614 - A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma Phase 1
Recruiting NCT03570502 - Incidence of POPF in the Resection of the Left Pancreas With RFAT
Completed NCT02468076 - Radiofrequency Ablation for Biliopancreatic Malignancy Phase 2
Completed NCT01446458 - Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer Phase 1
Completed NCT00500968 - Study Assessing the Effect of Transpapillary Pancreas Duct Stent in Resection of the Pancreatic Tail N/A
Recruiting NCT03484299 - Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma Phase 1
Active, not recruiting NCT02333279 - Cancer Development In Organ Transplant Recipients